Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind Randomized Phase III Study of Maintenance Pazopanib Versus Placebo in NSCLC Patients Non Progressive After First Line Chemotherapy. MAPPING, an EORTC Lung Group Study.

NCT01208064 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.

NCT NCT01208064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01208064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind Randomized Phase III Study of Maintenance Pazopanib Versus Placebo in NSCLC Patients Non Progressive After First Line Chemotherapy. MAPPING, an EORTC Lung Group Study.
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Phase
Phase 2/3
Overall status
Terminated
Start date
July 31, 2011
Completion date
June 30, 2015
Enrollment
102 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer